Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FL2C3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $98,898.60 by the Defense Logistics Agency on September 27, 2025, for the supply of Entyvio 300 mg vials. The contract utilizes a firm fixed-price structure with an ultimate completion date of October 20, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities nationwide.
Entyvio is a biologic medication used to treat inflammatory bowel diseases, and this delivery order supports the Department of Defense's pharmaceutical supply chain requirements. DMS Pharmaceutical Group has established itself as a critical supplier of branded and generic prescription drugs, biologics, and medical consumables to federal healthcare systems, with a demonstrated portfolio of successful contract awards across diverse therapeutic categories. The company's competitive positioning as a woman-owned small business, combined with its established presence in federal pharmaceutical procurement since 2001, enables it to effectively serve the Defense Logistics Agency's ongoing medical supply needs across military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DB25FL2C3?
SPE2DB25FL2C3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 27, 2025.
How much is contract SPE2DB25FL2C3 worth?
The government has obligated $98,899 on SPE2DB25FL2C3.
Is contract SPE2DB25FL2C3 an order under another contract?
Yes. SPE2DB25FL2C3 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL2C3 competed?
The extent of competition for SPE2DB25FL2C3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award